Interestingly, miR-17-92 showed high expression in CML-CP, but not in blast crisis CML-BC [38], despite this phase being characterised by increased BCR-ABL activity [39]. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.